PharmAla Biotech Holdings, Inc. (MDXXF) AI Stock Analysis

PharmAla Biotech Holdings, Inc.

(Other OTC:MDXXF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthRevenue growth shows that PharmAla is gaining commercial traction and increasing demand for its regulated products. If this expansion continues, greater scale could improve operating leverage, support reinvestment in the business, and strengthen its position in clinical and research supply markets.

Negative Factors

Persistent Operating LossesNegative gross profit and deeply negative operating earnings indicate that current revenue does not yet cover the cost structure. Without material improvement in pricing, product mix, or operating efficiency, revenue growth may continue to require external funding rather than translate into durable profitability.

PharmAla Biotech Holdings, Inc. (MDXXF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $18.57M
Dividend Yield: ―
Average Volume (3M): 33.64K
Price to Earnings (P/E): -11.4
Beta (1Y): 0.41
Revenue Growth: 231.15%
EPS Growth: 27.03%
Country: US
Employees: 5
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

PharmAla Biotech Holdings, Inc. Business Overview & Revenue Model

Company Description

Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The...

PharmAla Biotech Holdings, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MDXXF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:PHRM	48Neutral	CAD 5.01M	-13.10	-75.59%	―	―	75.84%
TSE:PREV	44Neutral	CAD 12.76M	-16.67	10.15%	―	―	-36.36%
TSE:CSCI	42Neutral	CAD 8.37M	-0.46	-48.52%	―	-13.00%	75.31%

* Healthcare Sector Average

Performance Comparison

MDXXF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MDXXF	PharmAla Biotech Holdings, Inc.	0.12	0.03	28.72%
TSE:CSCI	Cosciens Biopharma Inc.	8.40	-2.31	-21.57%
TSE:PREV	PreveCeutical Medical	0.02	-0.01	-33.33%
TSE:PHRM	PharmaTher Holdings Ltd	0.06	-0.06	-50.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

PharmAla Biotech Holdings, Inc. AI Stock Analysis